180 related articles for article (PubMed ID: 35241721)
21. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
22. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
[TBL] [Abstract][Full Text] [Related]
24. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate Cancer.
Gong P; Zhang T; He D; Hsieh JT
Radiat Res; 2015 Dec; 184(6):630-8. PubMed ID: 26632856
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
Sato H; Kasuya G; Ishikawa H; Nomoto A; Ono T; Nakajima M; Isozaki Y; Yamamoto N; Iwai Y; Nemoto K; Ichikawa T; Tsuji H;
Cancer Sci; 2021 Sep; 112(9):3598-3606. PubMed ID: 34107139
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
[TBL] [Abstract][Full Text] [Related]
28. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.
Rudner J; Ruiner CE; Handrick R; Eibl HJ; Belka C; Jendrossek V
Radiat Oncol; 2010 Nov; 5():108. PubMed ID: 21080918
[TBL] [Abstract][Full Text] [Related]
29. Comparison of treatment volumes and techniques in prostate cancer radiation therapy.
Lee CT; Dong L; Ahamad AW; Choi H; Cheung R; Lee AK; Horne DF; Breaux AJ; Kuban DA
Am J Clin Oncol; 2005 Dec; 28(6):618-25. PubMed ID: 16317275
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
31. [Options of hypofractionation of proton boost in locally advanced prostate cancer].
Khmelevskiĭ EV; Pan'shin GA; Kancheli IN; Khoroshkov VS
Vopr Onkol; 2012; 58(6):787-94. PubMed ID: 23600305
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
33. A cell-based high-throughput screening assay for radiation susceptibility using automated cell counting.
Hodzic J; Dingjan I; Maas MJ; van der Meulen-Muileman IH; de Menezes RX; Heukelom S; Verheij M; Gerritsen WR; Geldof AA; van Triest B; van Beusechem VW
Radiat Oncol; 2015 Feb; 10():55. PubMed ID: 25888875
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy.
Narayan V; Vapiwala N; Mick R; Subramanian P; Christodouleas JP; Bekelman JE; Deville C; Rajendran R; Haas NB
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):355-361. PubMed ID: 27986349
[TBL] [Abstract][Full Text] [Related]
35. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer.
Takemoto S; Shibamoto Y; Sugie C; Manabe Y; Yanagi T; Iwata H; Murai T; Ishikura S
J Radiat Res; 2019 Mar; 60(2):221-227. PubMed ID: 30566649
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation.
Tsai MH; Cook JA; Chandramouli GV; DeGraff W; Yan H; Zhao S; Coleman CN; Mitchell JB; Chuang EY
Cancer Res; 2007 Apr; 67(8):3845-52. PubMed ID: 17440099
[TBL] [Abstract][Full Text] [Related]
38. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
[TBL] [Abstract][Full Text] [Related]
39. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
[TBL] [Abstract][Full Text] [Related]
40. Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study.
Suetens A; Moreels M; Quintens R; Chiriotti S; Tabury K; Michaux A; Grégoire V; Baatout S
Int J Oncol; 2014 Apr; 44(4):1056-72. PubMed ID: 24504141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
